Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs... see more

TSX:TH - Post Discussion

View:
Post by stockman75 on Oct 20, 2022 9:22am

POC

What are chances TH1902 does not work but yet they establish POC? Is that an unlikely scenario? Hoping the keys didn't get jammed in the cancer door.
Comment by SPCEO1 on Oct 20, 2022 10:31am
There are quite a few possible scenarios for what the ultimate outcome will be from TH-1902 works well across all solid tumors to the keys getting stuck in the cancer door, which I imagine would mean starting over with a different payload. As time passes without news being announced, the possibility of really great news likely diminishes as you would expect protocol amendments to be announced ...more  
Comment by qwerty22 on Oct 20, 2022 11:27am
The obvious scenario is it could pass on efficacy and fail on safety. No evidence of that yet though. There are maybe a dozen important things it needs to pass on and any of them could lead to ultimate failure. But really it's a step-by-step process and we are atm investing in the next step of 2 responders from 10 with a continuing manageable safety profile. That would be a good base to build ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities